Kineta Inc (NAS:KA)

$ 0.4613 -0.0067 (-1.43%) Market Cap: 5.65 Mil Enterprise Value: 5.06 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 16/100

Kineta Inc KOL Event (Virtual) Transcript
Dec 05, 2023
Yumanity Therapeutics Inc to Discuss the Proposed Merger with Kineta Inc - Conference Call Transcript
Jun 06, 2022
Yumanity Therapeutics Inc YTX-7739 Topline Data Discussion Call Transcript
Nov 10, 2021
Yumanity Therapeutics Inc Annual Shareholders Meeting Transcript
Jun 02, 2021
Yumanity Therapeutics Inc Virtual Investor R&D Day Transcript
May 17, 2021
Proteostasis Therapeutics, Inc., Yumanity Therapeutics Inc. - M&A Call Transcript
Aug 24, 2020
Proteostasis Therapeutics Inc Call to Discuss Positive Phase 2 Topline Results from Proprietary CFTR Modulator Combinations in F508del Homozygous Cystic Fibrosis Patients Transcript
Dec 17, 2019
Proteostasis Therapeutics, Inc. - Special Call Transcript
Mar 25, 2019

Kineta Inc KOL Event (Virtual) Transcript

Dec 05, 2023 / 07:00PM GMT

Release Date Price: $4.35 (+1.64%)

Transcript

Operator

Good afternoon and welcome to the Kineta KOL event. (Operator Instructions) As a reminder, this event is being recorded and a replay will be made available after the event on the Kineta website.

I would now like to turn the call over to your host, Jacques Bouchy, EVP of Investor Relations and Business Development at Kineta. Please go ahead, sir.

Jacques Bouchy Kineta

Inc. - EVP, IR & Business Development

Thank you, Sarah, and good morning from Seattle, Washington and to those of you joining us on the West Coast, and good afternoon to all of those you've joining from around the rest of the country. I'm Jacques Bouchy, Executive Vice President of Investor Relations and Business Development in Kineta. I'd like to welcome you and thank you for joining us for today's KOL event to discuss VISTA, KVA12123, and initial results from our VISTA-101 clinical trial.

It is my distinct pleasure to introduce you our two key opinion leaders who will be joining our call today. First, Dr. Michael Curran is an Associate Professor of Immunology at the MD

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.